search
Back to results

Low-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD)

Primary Purpose

Generalized Anxiety Disorder

Status
Recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Active LIFUP Treatment
Sham LIFUP Treatment
Sponsored by
University of California, Los Angeles
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Generalized Anxiety Disorder focused on measuring focused ultrasound

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male or female Age 18-65 Normal or corrected-to normal vision and hearing Primary diagnosis of generalized anxiety disorder, moderate/severe per DSM-5. (HAM-A>17) 4a) The duration of the illness must exceed one year. Must be medically stable as determined by investigator Patient must have attempted and failed treatment with at least 2 SSRI and 1 augmentation History of rTMS is permitted, but not required. Exclusion Criteria: Diagnosis of primary DSM-5 anxiety disorder other than GAD 1a) Affective disorders such as unipolar or bipolar depression are permitted as long as GAD is primary Current use of any non-prescribed psychoactive medications or drugs (aside from medications for treatment of GAD) Contraindication to enter the MRI environment Pregnancy (or suspected/possible pregnancy or plan to become pregnant in the short-term) Inability to adhere to treatment schedule Initiation of new anxiolytic treatment at the time of study randomization

Sites / Locations

  • University of California, Los AngelesRecruiting
  • Massachusetts General HospitalRecruiting
  • Medical University of South CarolinaRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Sham Comparator

Arm Label

Low Intensity Focused Ultrasound

Sham

Arm Description

Device: Low Intensity Focused Ultrasound Device Low Intensity Focused Ultrasound Pulsation (LIFUP) of amygdala (a key area for anxiety) will be performed during two sessions. The proposed experiment will involve behavioral (e.g. HAM-A) and paramedical (i.e., MRI/fMRI) measurements just before and after each of the two LIFUP sessions (i.e., 5 non-consecutive minutes of stimulation in each session). The device does not produce a sound when operating and as such, the active group will well blinded.

Sham Treatment consists of placing the device but not turning it on. The device does not produce a sound when operating and as such, the sham group will well blinded.

Outcomes

Primary Outcome Measures

Hamilton Anxiety Rating Scale (HAM-A)
HAM-A is a rating scale for measuring the severity of anxiety symptoms.

Secondary Outcome Measures

Full Information

First Posted
September 15, 2020
Last Updated
August 4, 2023
Sponsor
University of California, Los Angeles
Collaborators
Massachusetts General Hospital, Medical University of South Carolina
search

1. Study Identification

Unique Protocol Identification Number
NCT04557891
Brief Title
Low-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD)
Official Title
Feasibility of Low-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD)
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Recruiting
Study Start Date
July 26, 2021 (Actual)
Primary Completion Date
December 2025 (Anticipated)
Study Completion Date
December 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
University of California, Los Angeles
Collaborators
Massachusetts General Hospital, Medical University of South Carolina

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Device Product Not Approved or Cleared by U.S. FDA
Yes
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
There are few treatment options available for patients once they have failed standard psychopharmacological therapy for generalized anxiety disorder. Existing brain stimulation methods such as rTMS fail to target deep brain structures associated with anxiety disorders; structures such as the amygdala. In this double-blind sham-controlled clinical trial, the investigators propose to establish baseline severity of anxiety in 48 patients, then deliver eight treatments over four sessions of focused ultrasound stimulation to the amygdala. Anxiety severity will be assessed using standard psychometric scales after each session, and at follow-ups.
Detailed Description
Anxiety disorders have tremendous disease burden in the United States. Up to 1 in 3 Americans will be diagnosed with an anxiety disorder in their lifetimes. Anxiety treatment is typically consisting of psychotherapy (e.g. cognitive behavioral therapy) and medication management (e.g. benzodiazepines, selective serotonin reuptake inhibitors, etc). With major depressive disorder, rTMS is a suitable alternative treatment for refractory depression, rTMS is not approved for treatment of anxiety, nor can rTMS stimulate deep enough to reach those brain circuits involved in anxiety (e.g. the amygdala). Focused ultrasound is a new treatment modality being developed for several different neuropsychiatric conditions. In this study, the investigators propose to randomize 48 individuals to either active or sham treatment. Each participant will be evaluated to establish a baseline diagnose of generalized anxiety disorder, and then will be reassessed after each treatment session (of which there are four). One week and one month after the last treatment session, the investigators will conduct follow-up evaluations.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Generalized Anxiety Disorder
Keywords
focused ultrasound

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
48 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Low Intensity Focused Ultrasound
Arm Type
Experimental
Arm Description
Device: Low Intensity Focused Ultrasound Device Low Intensity Focused Ultrasound Pulsation (LIFUP) of amygdala (a key area for anxiety) will be performed during two sessions. The proposed experiment will involve behavioral (e.g. HAM-A) and paramedical (i.e., MRI/fMRI) measurements just before and after each of the two LIFUP sessions (i.e., 5 non-consecutive minutes of stimulation in each session). The device does not produce a sound when operating and as such, the active group will well blinded.
Arm Title
Sham
Arm Type
Sham Comparator
Arm Description
Sham Treatment consists of placing the device but not turning it on. The device does not produce a sound when operating and as such, the sham group will well blinded.
Intervention Type
Device
Intervention Name(s)
Active LIFUP Treatment
Other Intervention Name(s)
BX Pulsar 1002
Intervention Description
8 LIFUP Treatments
Intervention Type
Device
Intervention Name(s)
Sham LIFUP Treatment
Intervention Description
8 sham LIFUP treatments
Primary Outcome Measure Information:
Title
Hamilton Anxiety Rating Scale (HAM-A)
Description
HAM-A is a rating scale for measuring the severity of anxiety symptoms.
Time Frame
1 week after the fourth LIFUP treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female Age 18-65 Normal or corrected-to normal vision and hearing Primary diagnosis of generalized anxiety disorder, moderate/severe per DSM-5. (HAM-A>17) 4a) The duration of the illness must exceed one year. Must be medically stable as determined by investigator Patient must have attempted and failed treatment with at least 2 SSRI and 1 augmentation History of rTMS is permitted, but not required. Exclusion Criteria: Diagnosis of primary DSM-5 anxiety disorder other than GAD 1a) Affective disorders such as unipolar or bipolar depression are permitted as long as GAD is primary Current use of any non-prescribed psychoactive medications or drugs (aside from medications for treatment of GAD) Contraindication to enter the MRI environment Pregnancy (or suspected/possible pregnancy or plan to become pregnant in the short-term) Inability to adhere to treatment schedule Initiation of new anxiolytic treatment at the time of study randomization
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Margaret G Distler, MD,PhD
Phone
(310) 794-1553
Email
mdistler@mednet.ucla.edu
First Name & Middle Initial & Last Name or Official Title & Degree
Andrew Swenson, BS
Phone
(310) 206-5133
Email
aswenson@mednet.ucla.edu
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Margaret G Distler, MD,PhD
Organizational Affiliation
University of California, Los Angeles
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Taylor P Kuhn, PhD
Organizational Affiliation
University of California, Los Angeles
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of California, Los Angeles
City
Los Angeles
State/Province
California
ZIP/Postal Code
90095
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Margaret G Distler, MD, PhD
Phone
310-794-1553
Email
mdistler@mednet.ucla.edu
First Name & Middle Initial & Last Name & Degree
Andrew Swenson
Phone
3102065133
Email
aswenson@mednet.ucla.edu
First Name & Middle Initial & Last Name & Degree
Margaret G Distler, MD,PhD
First Name & Middle Initial & Last Name & Degree
Taylor P Kuhn, PhD
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02129
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Tina Chou, PhD
Email
tchou@mgh.harvard.edu
First Name & Middle Initial & Last Name & Degree
Darin D Dougherty, MD
First Name & Middle Initial & Last Name & Degree
Tina Chou, PhD
Facility Name
Medical University of South Carolina
City
Charleston
State/Province
South Carolina
ZIP/Postal Code
29425
Country
United States
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Bridgette Holland
Phone
843-638-7517
Email
hollanbr@musc.edu
First Name & Middle Initial & Last Name & Degree
Mark S George, MD

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Low-Intensity Focused Ultrasound Pulsation (LIFUP) for the Treatment of Generalized Anxiety Disorder (GAD)

We'll reach out to this number within 24 hrs